Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis

Inclusion Criteria: * Patients with cytologically or histologically documented HCC, who are candidates for TACE * Child-Pugh Child A or B * Age \>= 18 * Measurable disease by RECIST criteria; * Performance status ECOG 0-2 * Previous local therapy completed \> 4 weeks * Written informed consent signed * Normal organ and marrow function defined as: Haematopoietic: * WBC ≥ 3,000/µlplatelet count \> 80,000/mm3 * haemoglobin \> 9g/dL * Hepatic: Albumin ≥ 2.8 g/dl.serum total bilirubin ≤ 3 mg/dl; AST or ALT \< 5 x ULN * Renal: creatinine \< 1.5 x ULN Exclusion Criteria: * Metastases * Prior or concomitant chemotherapy or radiation therapy * VEGF/VEGFR- inhibitors or other anti-angiogenesis agents * Severe and/or uncontrolled medical conditions: * Congestive heart failure, serious cardiac arrhythmia, active coronary artery * Severe renal impairment * Patients who anticipate receiving major surgery during the course of the * Pregnant or breastfeeding patients * Evidence of bleeding diathesis